全文获取类型
收费全文 | 1787篇 |
免费 | 92篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 59篇 |
妇产科学 | 53篇 |
基础医学 | 291篇 |
口腔科学 | 32篇 |
临床医学 | 120篇 |
内科学 | 276篇 |
皮肤病学 | 52篇 |
神经病学 | 142篇 |
特种医学 | 47篇 |
外科学 | 282篇 |
综合类 | 13篇 |
预防医学 | 224篇 |
眼科学 | 39篇 |
药学 | 172篇 |
中国医学 | 2篇 |
肿瘤学 | 73篇 |
出版年
2021年 | 36篇 |
2020年 | 21篇 |
2019年 | 32篇 |
2018年 | 34篇 |
2017年 | 27篇 |
2016年 | 23篇 |
2015年 | 27篇 |
2014年 | 51篇 |
2013年 | 44篇 |
2012年 | 93篇 |
2011年 | 99篇 |
2010年 | 52篇 |
2009年 | 39篇 |
2008年 | 75篇 |
2007年 | 67篇 |
2006年 | 71篇 |
2005年 | 77篇 |
2004年 | 74篇 |
2003年 | 66篇 |
2002年 | 77篇 |
2001年 | 64篇 |
2000年 | 49篇 |
1999年 | 41篇 |
1998年 | 15篇 |
1995年 | 16篇 |
1992年 | 29篇 |
1991年 | 28篇 |
1990年 | 26篇 |
1989年 | 23篇 |
1988年 | 23篇 |
1987年 | 21篇 |
1986年 | 25篇 |
1985年 | 21篇 |
1984年 | 16篇 |
1983年 | 18篇 |
1980年 | 11篇 |
1979年 | 24篇 |
1978年 | 16篇 |
1977年 | 11篇 |
1976年 | 15篇 |
1975年 | 17篇 |
1974年 | 15篇 |
1973年 | 20篇 |
1972年 | 15篇 |
1971年 | 22篇 |
1970年 | 22篇 |
1969年 | 23篇 |
1968年 | 21篇 |
1967年 | 24篇 |
1966年 | 12篇 |
排序方式: 共有1890条查询结果,搜索用时 218 毫秒
1.
Rolf Svedjeholm Gabriele Ferrari Farkas Vanky Örjan Friberg Jonas Holm 《Acta anaesthesiologica Scandinavica》2023,67(10):1373-1382
Background
Glutamate plays a key role for post-ischaemic recovery of myocardial metabolism. According to post hoc analyses of the two GLUTAMICS trials, patients without diabetes benefit from glutamate with less myocardial dysfunction after coronary artery bypass surgery (CABG). Copeptin reflects activation of the Arginine Vasopressin system and is a reliable marker of heart failure but available studies in cardiac surgery are limited. We investigated whether glutamate infusion is associated with reduced postoperative rises of plasma Copeptin (p-Copeptin) after CABG.Methods
A prespecified randomised double-blind substudy of GLUTAMICS II. Patients had left ventricular ejection fraction ≤0.30 or EuroSCORE II ≥3.0 and underwent CABG ± valve procedure. Intravenous infusion of 0.125 M L-glutamic acid or saline at 1.65 mL/kg/h was commenced 10–20 min before the release of the aortic cross-clamp and then continued for another 150 min P-Copeptin was measured preoperatively and postoperatively on day one (POD1) and day three. The primary endpoint was an increase in p-Copeptin from the preoperative level to POD1. Postoperative stroke ≤24 h and mortality ≤30 days were safety outcomes.Results
We included 181 patients of whom 48% had diabetes. The incidence of postoperative mortality ≤30 days (0% vs. 2.1%; p = .50) and stroke ≤24 h (0% vs. 3.2%; p = .25) did not differ between the glutamate group and controls. P-Copeptin increased postoperatively with the highest values recorded on POD1 without significant inter-group differences. Among patients without diabetes, p-Copeptin did not differ preoperatively but postoperative rise from preoperative level to POD1 was significantly reduced in the glutamate group (73 ± 66 vs. 115 ± 102 pmol/L; p = .02). P-Copeptin was significantly lower in the Glutamate group on POD1 (p = .02) and POD 3 (p = .02).Conclusions
Glutamate did not reduce rises of p-Copeptin significantly after moderate to high-risk CABG. However, glutamate was associated with reduced rises of p-Copeptin among patients without diabetes. These results agree with previous observations suggesting that glutamate mitigates myocardial dysfunction after CABG in patients without diabetes. Given the exploratory nature of these findings, they need to be confirmed in future studies. 相似文献2.
Paul Overdorf Jr. Gary J. Farkas Natasha Romanoski 《The journal of spinal cord medicine》2020,43(3):398-401
Context: Autonomic dysreflexia and dysautonomia can be a common complication following spinal cord injury, especially at levels of T6 and above and can lead to complications associated with the pupil. In this case report, we review autonomic dysreflexia, the anatomy and physiology of the sympathetic nervous system of the eye, as well as review the clinical relevance in understanding autonomic and pupillary changes in response to autonomic dysfunction.Findings: We present a patient with an incomplete C4 level injury who was found to have isolated anisocoria on two separate occasions during his acute inpatient rehabilitation stay.Conclusion/Clinical Relevance: Anisocoria associated with abnormal sympathetic activation may be a clinical sign of dysautonomia. 相似文献
3.
4.
5.
6.
Pratt VM Zehnbauer B Wilson JA Baak R Babic N Bettinotti M Buller A Butz K Campbell M Civalier C El-Badry A Farkas DH Lyon E Mandal S McKinney J Muralidharan K Noll L Sander T Shabbeer J Smith C Telatar M Toji L Vairavan A Vance C Weck KE Wu AH Yeo KT Zeller M Kalman L 《The Journal of molecular diagnostics : JMD》2010,12(6):835-846
Pharmacogenetic testing is becoming more common; however, very few quality control and other reference materials that cover alleles commonly included in such assays are currently available. To address these needs, the Centers for Disease Control and Prevention's Genetic Testing Reference Material Coordination Program, in collaboration with members of the pharmacogenetic testing community and the Coriell Cell Repositories, have characterized a panel of 107 genomic DNA reference materials for five loci (CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1) that are commonly included in pharmacogenetic testing panels and proficiency testing surveys. Genomic DNA from publicly available cell lines was sent to volunteer laboratories for genotyping. Each sample was tested in three to six laboratories using a variety of commercially available or laboratory-developed platforms. The results were consistent among laboratories, with differences in allele assignments largely related to the manufacturer's assay design and variable nomenclature, especially for CYP2D6. The alleles included in the assay platforms varied, but most were identified in the set of 107 DNA samples. Nine additional pharmacogenetic loci (CYP4F2, EPHX1, ABCB1, HLAB, KIF6, CYP3A4, CYP3A5, TPMT, and DPD) were also tested. These samples are publicly available from Coriell and will be useful for quality assurance, proficiency testing, test development, and research. 相似文献
7.
8.
M. Speletas Á. Szilágyi D. Csuka N. Koutsostathis F. Psarros D. Moldovan M. Magerl M. Kompoti L. Varga M. Maurer H. Farkas A. E. Germenis 《Allergy》2015,70(12):1661-1664
The factors influencing the heterogeneous clinical manifestation of hereditary angioedema due to C1‐INH deficiency (C1‐INH‐HAE) represent one of the oldest unsolved problems of the disease. Considering that factor XII (FXII) levels may affect bradykinin production, we investigated the contribution of the functional promoter polymorphism F12‐46C/T in disease phenotype. We studied 258 C1‐INH‐HAE patients from 113 European families, and we explored possible associations of F12‐46C/T with clinical features and the SERPING1 mutational status. Given that our cohort consisted of related subjects, we implemented generalized estimating equations (GEEs), an extension of the generalized linear model accounting for the within‐subject correlation. F12‐46C/T carriers exhibited a significantly delayed disease onset (P < 0.001) and did not need long‐term treatment (P = 0.02). In a GEE linear regression model, the presence of F12‐46C/T was significantly associated with a 7‐year delay in disease onset (P < 0.0001) regardless of SERPING1 mutational status. It is concluded that F12‐46C/T carriage acts as an independent modifier of C1‐INH‐HAE severity. 相似文献
9.
Iris Schrijver Nazneen Aziz Daniel H. Farkas Manohar Furtado Andrea Ferreira Gonzalez Timothy C. Greiner Wayne W. Grody Tina Hambuch Lisa Kalman Jeffrey A. Kant Roger D. Klein Debra G.B. Leonard Ira M. Lubin Rong Mao Narasimhan Nagan Victoria M. Pratt Mark E. Sobel Karl V. Voelkerding Jane S. Gibson 《The Journal of molecular diagnostics : JMD》2012,14(6):525-540
10.